TY  - JOUR
AU  - Mooradian, Meghan J.
AU  - Gainor, Justin F.
PY  - 2018
TI  - Putting the brakes on CTLA-4 inhibition in lung cancer?
JF  - Translational Lung Cancer Research; Vol 7, Supplement 1 (February 11, 2018): Translational Lung Cancer Research
Y2  - 2018
KW  - 
N2  - Immune checkpoint inhibitors have fundamentally changed the treatment landscape of non-small cell lung cancer (NSCLC). Indeed, within the last 3 years, single-agent programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors have become standard therapies in both the first- and second-line settings for patients with advanced disease (1-4). Despite these advancements, however, only a minority of patients experience durable responses to PD-1 pathway inhibition.
UR  - https://tlcr.amegroups.org/article/view/18728